No products in the cart.
Pre-made Volociximab benchmark antibody (Whole mAb, anti-ITGA5 therapeutic antibody, Anti-CD49eRA/VLA-5/VLA5A Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-1049
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-ITGA5 therapeutic antibody (Pre-made Volociximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Volociximab (also known as M2) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of ¦Á5¦Â1 integrin.[1]
| Products Name (INN Index) | Pre-Made Volociximab Biosimilar, Whole Mab, Anti-Itga5 Antibody: Anti-CD49eRA/VLA-5/VLA5A therapeutic antibody |
|---|---|
| INN Name | volociximab |
| Target | ITGA5 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 – nd |
| VD LC | IgG4 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ITGA5 |
| Package |
Previous slide
Next slide
